Phase 2
Completed N=12
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Lymphoma, Non-Hodgkin
Source: ClinicalTrials.gov NCT00426855 ↗
Enrolled (actual)
12
Serious AEs
8.3%
Results posted
Apr 2015
Primary outcomePrimary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2
Summary
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Optimal Bendamustine Dosage for Further Studies |
60 | — |
Eligibility Criteria
Inclusion Criteria
- Symptomatic recurrent or refractory indolent NHL or B-CLL
- Adequate organ and bone marrow function
- Karnofsky greater than 50%
Exclusion Criteria
- Candidates for autologous stem cell transplantation
- Secondary high grade lymphoma
- Concurrent severe medical condition
Data sourced from ClinicalTrials.gov (NCT00426855). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.